Could a vaccine stop breast cancer before it starts? new trial launches

NCT ID NCT06218303

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing whether a vaccine targeting the MUC1 protein, combined with hormone therapy, can help prevent ductal carcinoma in situ (DCIS) from becoming invasive breast cancer. Fifty women with ER-positive DCIS will receive either hormone therapy alone or hormone therapy plus the vaccine before surgery. The main goal is to see if the vaccine boosts the immune system's response against cancer cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MUC1 peptide vaccine combined with Hiltonol® (an immune booster) and hormone therapy (aromatase inhibitor or SERM)
What this could lead to
If it works, this could lead to a vaccine that prevents ductal carcinoma in situ from progressing to invasive breast cancer, reducing the need for surgery.
What could go wrong
This is a very early phase 1 trial with only 50 participants, so it is too small to prove effectiveness. The vaccine may not trigger a strong enough immune response, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCTAL CARCINOMA IN SITU are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UPMC Magee Womens Hospital

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.